Ken Griffin Neoleukin Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$0.68 - $0.91 $6,188 - $8,281
-9,100 Reduced 65.94%
4,700 $3,000
Q1 2023

May 15, 2023
BUY
$0.5 - $0.72 $6,900 - $9,936
13,800 New
13,800 $9,000

Others Institutions Holding NLTX

# of Institutions
1
Shares Held
199K
Call Options Held
0
Put Options Held
0
View Full List

About Neoleukin Therapeutics, Inc.

NLTX Quotes by TradingView
  • Ticker NLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 42,579,900
  • Description
  • Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...
More about NLTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email